Added to YB: 2026-03-09
Pitch date: 2026-03-06
QURE [neutral]
uniQure N.V.
-5.97%
current return
Author Info
No bio for this author
Company Info
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States.
Market Cap
$1.1B
Pitch Price
$18.02
Price Target
N/A
Dividend
N/A
EV/EBITDA
-6.69
P/E
-5.28
EV/Sales
65.59
Sector
Biotechnology
Category
special_situation
uniQure: Some hope yet for bulls?
QURE (update): UK Gov Office for Science officially backs AMT-130 gene therapy for Huntington's. NIHR/DHSC-funded study showed 75% less disease progression at 3yrs in high-dose patients vs controls. UK statement directly challenges FDA's sham-procedure RCT demand, citing robust observational comparison group. First gene therapy tested in Huntington's; 8K UK patients, no prior treatments slow progression.
Read full article (2 min)